Table 2.
Clinical and biological features of patients with hypodiploid ALL.
| Study | Near-Haploid | Low-Hypodiploid | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M/F 1 | Age | WBC (×109/L) * | PreB/T Lineage | M/F 1 | Age | WBC (×109/L) * | PreB/T Lineage | |||||||||
| M 2 | <10 yo at dx * | M 2 | ≤20 | 20–50 | >50 | M 2 | <10 yo at dx * | M 2 | ≤20 | 20–50 | >50 | |||||
| SJCRH [16] | nr | 4.5 | 3 | nr | nr | nr | 11 | 1 | nr | nr | ||||||
| SJCRH-POG [17] | 0.66 | 4.7 | 70 | 13 | 70 | 10 | 20 | 8/13 | 2 | 10.5 | 22.2 | 8.4 | 66.6 | 11.1 | 22.2 | 5/1 3 |
| CCG [19] | 63 | 50 | 13 | 38 | nr | nr | nr | nr | ||||||||
| SJCRH [20] | 7.3 | 100 | 2.5 | 100 | 0 | 0 | 4/0 | nr | 0 | 8.2 | 83.3 | 0 | 16.6 | 5/1 | ||
| MRC [21] | 0.75 | 7.4 | 64.3 | 67.3 | 38.5 | 30.8 | 30.8 | 13/0 3 | 1.1 | 21.6 | 7.1 | 11 | 85.7 | 7.1 | 7.1 | 12/0 3,4 |
| Inc study [22] | 1 | 69.6 | 39.1 | 41.3 | 19.6 | nr | 2.25 | 19.2 | 73 | 19.2 | 7.7 | nr | ||||
| SJTTS 15&16 [23] | 3.6 | 8.1 | 13.9 | 5.6 | ||||||||||||
| PDLWG [24] | 1.46 | 6.2 | 73 | 21.8 | 49 | 20 | 31 | 99/1 | 1.14 | 12.9 | 26 | 7 | 85 | 10 | 4 | 99/1 |
| Japanese study [25] | nr | nr | nr | nr | nr | nr | nr | 3/0 | nr | nr | nr | nr | nr | nr | nr | 3/0 |
* Percentage of patients. 1 Male-to-female-ratio. 2 Median. 3 data not available from 4 patients in the SJCRH-PG study and in 1 patient in the MRC study. 4 one patient reported as “null” immunophenotype. Abbreviations: CCG, Children Cancer Group; CIBMTR, Centre for International Blood and Marrow Transplant Research; CNS, central nervous system; LH; low-hypodiploid; MRC, Medical Research Council; na, not applicable; NH, near-haploid; nr, not reported; PDLWG, Ponte di Legno childhood ALL Working group; POG, Pediatric Oncology Group; preB, B-cell precursor; SJCRH, Saint Jude Children’s Research Hospital; SJTTS, Saint Jude Total Therapy Study; WBC, white blood cell count at presentation.